文献速递乳腺癌支持与姑息治疗

高危早期乳腺癌辅助唑来膦酸5年对比2年:III期随机试验预后结果

Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

SUCCESS A是一项2×2析因设计的III期多中心随机开放标签试验,纳入3754例接受辅助化疗的高危早期乳腺癌患者,二次随机比较唑来膦酸5年与2年治疗。最终分析2987例,中位年龄53岁,两组无病生存、总生存、无远处复发生存均无显著差异,5年组不良事件更多,提示超过2年延长唑来膦酸治疗不改善预后。

要点

  • 高危早期乳腺癌辅助化疗后,唑来膦酸5年对比2年未显著改善无病生存、总生存和无远处复发生存。
  • 5年组不良事件发生率46.2%,高于2年组27.2%,骨痛和关节痛更常见。
  • 结果提示现行推荐的3至5年双膦酸盐疗程或可缩短,但需结合指南与个体风险评估。

核心结论

  • 在高危早期乳腺癌接受辅助化疗的患者中,唑来膦酸治疗超过2年未改善预后,提示现行推荐的3至5年双膦酸盐疗程可能可以缩短。

研究设计与样本

  • SUCCESS A为III期多中心随机开放标签2×2析因试验,2005年9月21日至2007年3月12日入组3754例,最终分析2987例,中位年龄53岁(范围21-86岁)。

主要发现

  • 5年组与2年组无病生存无显著差异(HR 0.97,95%CI 0.75-1.25,P=.81)。
  • 总生存无显著差异(HR 0.98,95%CI 0.67-1.42,P=.90)。
  • 无远处复发生存无显著差异(HR 0.87,95%CI 0.65-1.18,P=.38)。
  • 不良事件5年组46.2%高于2年组27.2%,骨痛分别为8.3%与3.7%,关节痛分别为5.1%与3.1%。

关键数值与推荐

  • 入组条件为淋巴结阳性或高危淋巴结阴性原发浸润性乳腺癌,高危淋巴结阴性定义为至少满足肿瘤大小≥pT2、组织学分级3级、激素受体阴性或年龄≤35岁之一。
  • 唑来膦酸5年方案为4 mg静脉每3个月一次共2年,随后4 mg静脉每6个月一次共3年;2年方案为4 mg静脉每3个月一次共2年。
  • 生存时间自唑来膦酸治疗开始后2年起计算(landmark分析)。

临床怎么用

  • 高危早期乳腺癌辅助化疗后使用唑来膦酸,2年疗程与5年疗程预后相当,可考虑不延长超过2年以减少不良事件。
  • 临床决策仍需结合现行指南推荐、骨折风险与个体耐受性综合评估。

局限性

  • 原文摘要未报告具体局限性描述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. OBJECTIVE: To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patients with early breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The SUCCESS A phase 3 multicenter randomized open-label clinical trial with a 2 × 2 factorial design enrolled 3754 patients from September 21, 2005, to March 12, 2007 (last patient out, May 7, 2014). Final data analysis was conducted from September 2019 to October 2020. In 250 German study centers, patients were eligible for participation in the SUCCESS A trial if they had either node-positive or high-risk node-negative (defined as at least 1 of the following: tumor size ≥ pT2, histologic grade 3, negative hormone receptor status, or age ≤35 years) primary invasive breast cancer. INTERVENTIONS: Patients were first randomized to adjuvant chemotherapy with 3 cycles of fluorouracil, epirubicin, and cyclophosphamide followed by 3 cycles of docetaxel with or without gemcitabine (not presented in this report). After chemotherapy, patients underwent a second randomization of 5 years of zoledronate treatment (4 mg intravenously every 3 months for 2 years, followed by 4 mg intravenously every 6 months for 3 years) vs 2 years of zoledronate treatment (4 mg intravenously every 3 months for 2 years). MAIN OUTCOMES AND MEASURES: The primary end point of the study was disease-free survival; secondary end points were overall survival, distant disease-free survival, and the incidence of skeletal-related adverse events. Survival times were measured from 2 years after the start of zoledronate treatment (landmark analysis). RESULTS: Overall, data on 2987 patients were available for analysis; median age was 53 (range, 21-86) years. Disease-free survival, overall survival, and distant disease-free survival did not differ significantly between the 2 treatment arms (5 vs 2 years) as shown by adjusted multivariable Cox proportional hazards regression models (disease-free survival: hazard ratio [HR], 0.97; 95% CI, 0.75-1.25; P = .81; overall survival: HR, 0.98; 95% CI, 0.67-1.42; P = .90; distant disease-free survival: HR, 0.87; 95% CI, 0.65-1.18; P = .38). Adverse events were observed more often in the 5-year (46.2%) vs 2-year (27.2%) zoledronate treatment arm, which was particularly true for the skeletal-related events bone pain (5 years, 8.3% vs 2 years, 3.7%) and arthralgia (5 years, 5.1% vs 2 years, 3.1%). CONCLUSIONS AND RELEVANCE: The results of this phase 3 randomized clinical trial indicate that extending the zoledronate treatment beyond 2 years does not improve the prognosis of high-risk patients with early breast cancer receiving chemotherapy, suggesting that the currently recommended bisphosphonate treatment duration of 3 to 5 years could be reduced. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02181101.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Friedl TWP, Fehm T, Müller V, et al. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34165508. doi:10.1001/jamaoncol.2021.1854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。